Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

174.56USD
24 Feb 2017
Change (% chg)

$0.55 (+0.32%)
Prev Close
$174.01
Open
$173.29
Day's High
$174.72
Day's Low
$172.48
Volume
2,677,307
Avg. Vol
3,977,868
52-wk High
$176.85
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $128,555.20
Shares Outstanding(Mil.): 736.45
Dividend: 1.15
Yield (%): 2.64

Financials

  AMGN.O Industry Sector
P/E (TTM): 17.01 44.08 29.63
EPS (TTM): 10.26 -- --
ROI: 11.95 -3.35 12.96
ROE: 26.65 5.80 14.11

AARP, Eli Lilly support Sanofi, Regeneron in cholesterol drug fight

Seniors' advocacy group AARP and drugmaker Eli Lilly & Co on Thursday urged a federal appeals court to overturn a court order barring sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent.

Feb 24 2017

Fitch Affirms Astrazeneca at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, February 22 (Fitch) Fitch Rating has affirmed UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating at 'A'. The Outlook is Stable. The rating remains underpinned by AZ's leading position in the global pharmaceutical sector, supported by a business risk profile characterised by scale, diversification, and focus on innovation. The group is accelerating the dev

Feb 22 2017

BRIEF-Amgen Inc files for potential mixed shelf size not disclosed

* Amgen Inc - files for potential mixed shelf; size not disclosed Source text:(http://bit.ly/2lhl0EQ) Further company coverage:

Feb 14 2017

BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on

* Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017"

Feb 09 2017

UPDATE 2-Regeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales

Feb 8 A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, while they appeal the order.

Feb 08 2017

Regeneron, Sanofi win stay of order blocking cholesterol drug sales

Feb 8 A U.S. appeals court on Wednesday has stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, later this month while they appeal.

Feb 08 2017

FDA approves Amgen drug for secondary hyperparathyroidism

The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday.

Feb 07 2017

BRIEF-FDA approves Amgen's Parsabiv, first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis

* FDA approves Amgen's Parsabiv (etelcalcetide), first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis

Feb 07 2017

U.S. FDA approves Amgen drug for secondary hyperparathyroidism

Feb 7 The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday.

Feb 07 2017

BRIEF-Amgen appoints Charles Holley Jr. to board of directors

* Amgen announces appointment of Charles M. Holley Jr. To board of directors

Feb 03 2017

More From Around the Web

Earnings vs. Estimates